We thank Dr. Kawada for his comments and inquiry on our article.1 Our report of plasma and exosomal axonal, inflammatory, and vascular biomarkers is part of a discovery project studying candidate biomarkers of remote mild TBI (mTBI) outcomes among service members and veterans with combat-related mTBI enrolled in the Chronic Effects of Neurotrauma Consortium longitudinal study. This study complemented our previous report that evaluated biomarkers associated with neurodegeneration tau, hyperphosphorylated tau, and beta amyloid-40 and beta amyloid-42.2 The samples in this analysis were obtained a mean of 8 years after the most severe combat-related mTBI. By contrast, the specimens in the earlier study by Gill et al.3 were obtained much earlier from service members who had sustained an mTBI within the previous 3 years. In addition to the difference in mean time since injury, there were other methodological differences between the studies. All results are preliminary and require validation in a larger cohort.